Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetic Retinopathy, Diabetes Mellitus, Type 2, Glaucoma
Interventions
Behavioral Activation, Supportive Therapy
Behavioral
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Conditions
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Interventions
Ziltivekimab, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
188
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 156 more
Conditions
Suicide, Interpersonal Relations
Interventions
VA Standard Suicide Intervention, Treatment for Relationships and Safety Together (TR&ST)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Diego, California
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
807 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Low Back Pain, Myofascial Pain Syndrome Lower Back
Interventions
Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below., Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below., Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
Drug
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Obesity
Interventions
BMS-646256, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Augusta, Georgia + 7 more
Conditions
Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
Interventions
Prexasertib, Cyclophosphamide, Gemcitabine, filgrastim, peg-filgrastim
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 24 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Non ST Elevation Myocardial Infarction
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
Medical University of Silesia
Other
Eligibility
21 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, PSMA PET Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET-CT Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
San Francisco, California • Sylmar, California • Seattle, Washington
Conditions
Knee Osteoarthritis
Interventions
Physical Therapy, Platelet-Rich Plasma Injection, Photobiomodulation Therapy
Other · Biological · Device
Lead sponsor
Musculoskeletal Injury Rehabilitation Research for Operational Readiness
Federal
Eligibility
18 Years to 64 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenosquamous Carcinoma
Interventions
Autologous DC Therapy
Biological
Lead sponsor
Diakonos Oncology Corporation
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Houston, Texas
Conditions
Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Castration-Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma, Adenocarcinoma of the Prostate, Localized Prostate Carcinoma, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma, Advanced Prostate Cancer, Advanced Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate, Lutetium Lu 177 Vipivotide Tetraxetan, Prednisone, PSMA PET-CT Scan, Quality-of-Life Assessment, Single Photon Emission Computed Tomography
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Acute Coronary Syndrome
Interventions
fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
3,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Ocala, Florida • Albuquerque, New Mexico • Syracuse, New York + 1 more
Conditions
Severe Combined Immunodeficiency, Malignancy, Hematologic, Neuroblastoma, Neoplasm, Mucopolysaccharidosis I
Interventions
Venipuncture
Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Peripheral Neuropathy
Interventions
Immediate St (Scrambler Therapy), Waitlist ST (Scrambler Therapy)
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Agitation
Interventions
acupuncture, sham acupuncture
Device
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Months to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Solid, Liquid, Central Nervous System Tumors
Interventions
Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, Return of Results Follow-Up Visits, Blood Sample, Skin Biopsy
Other · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2053
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Eating Disorders, Eating Disorders Symptoms
Interventions
Bilateral Stimulation
Behavioral
Lead sponsor
San Francisco State University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Completed Not applicable Interventional Results available

Stroke and CPAP Outcome Study 3

NCT06029959
Conditions
Ischemic Stroke, Intra Cerebral Hemorrhage, Obstructive Sleep Apnea, Adherence, Treatment, Motivation
Interventions
Continuous positive airway pressure (CPAP), CPAP technical support intervention, Motivational Enhancement Therapy (MET), Mobile Health intervention
Device · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Accepts healthy volunteers

Inspiring Seniors Toward Exercise Promotion

NCT06364189
Conditions
Cognitively Normal Older Adults
Interventions
Music, Exercise
Behavioral
Lead sponsor
University of North Carolina, Greensboro
Other
Eligibility
65 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Greensboro, North Carolina
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, melphalan, thalidomide, autologous-autologous tandem hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
29
States / cities
Hartford, Connecticut • Beech Grove, Indiana • Richmond, Indiana + 21 more
Conditions
Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma, Unresectable Meningioma
Interventions
Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Computed Tomography, Biospecimen Collection, Single Photon Emission Computed Tomography
Radiation · Drug · Procedure + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
HIV/AIDS, Diabetes Mellitus, Hypertension, Substance Use
Interventions
Patient Navigation
Behavioral
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
New York, New York